Evaxion (NASDAQ: EVAX) elevates CSO Birgitte Rønø to combined CSO and COO role

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has promoted Chief Scientific Officer Birgitte Rønø to a dual role as Chief Scientific and Chief Operating Officer. This change follows an internal management review aimed at aligning the organization to better execute its strategy and increase external visibility of its AI-Immunology™ platform with partners and investors.

The promotion recognizes Dr. Rønø’s long-standing contribution to Evaxion’s internal operations and scientific leadership. Following the change, the management team consists of CEO Helen Tayton-Martin, CSO and COO Birgitte Rønø, CFO Thomas Schmidt, and Chief AI Officer Andreas Mattsson. The filing also reiterates Evaxion’s focus on AI-driven vaccine candidates for cancer and infectious diseases.

Key Figures

Team size: More than 40 experts Contact phone: +45 53 54 82 96

2 metrics

Team size More than 40 experts Covers value chain from target discovery to clinical development

Contact phone +45 53 54 82 96 Investor Relations & Communication contact for Evaxion A/S

Key Terms

AI-Immunology™, clinical-stage TechBio company, prophylactic vaccine candidates, forward-looking statements

4 terms

AI-Immunology™ technical

"a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform"

ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.

clinical-stage TechBio company financial

"Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines"

prophylactic vaccine candidates medical

"as well as prophylactic vaccine candidates for infectious diseases"

forward-looking statements regulatory

"This announcement contains forward-looking statements within the meaning of Section 27A"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On April 27, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: April 27, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

• Management remit expansion reflecting organization alignment to maximize external engagement and strategy execution
  

COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on the dual responsibilities of CSO and Chief Operating Officer (COO).

The promotion follows an internal management review of the optimal way of working to continue to deliver Evaxion’s strategy through broader external visibility of the power of the AI-Immunology™ platform with partners and investors. It also reflects the recognition of Dr Rønø’s long and extensive contribution to the internal operation of Evaxion over many years.

“I am delighted to announce the promotion of Dr Rønø to the dual role of CSO and COO, reflecting her long contribution to the efficient operation of the company coupled with her deep scientific expertise. Alongside the considerable expertise of the other members of the Evaxion management team, this change leaves us very well placed to continue building and broadening awareness of Evaxion’s unique AI capabilities in immune target discovery, vaccine and other drug product candidate design through to early preclinical and clinical validation,” says Helen Tayton-Martin, CEO of Evaxion.

Following the promotion, Evaxion’s management team remains composed of the following members:

• Helen Tayton-Martin, CEO
• Birgitte Rønø, CSO and COO
• Thomas Schmidt, CFO
• Andreas Mattsson, Chief AI Officer

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What leadership change did Evaxion (EVAX) announce in this Form 6-K?

Evaxion announced that Chief Scientific Officer Birgitte Rønø has been promoted to a dual role as Chief Scientific and Chief Operating Officer. The change follows an internal management review focused on optimizing strategy execution and external visibility of the company’s AI-Immunology™ platform.

How does Birgitte Rønø’s new role align with Evaxion’s strategy?

Her expanded remit as both CSO and COO is intended to support Evaxion’s strategy by strengthening organizational alignment and enhancing external engagement. The company highlights her long operational contributions and scientific expertise in showcasing its AI-Immunology™ platform to partners and investors.

Who is currently on Evaxion (EVAX)’s management team?

Evaxion’s management team comprises CEO Helen Tayton-Martin, CSO and COO Birgitte Rønø, CFO Thomas Schmidt, and Chief AI Officer Andreas Mattsson. This group covers executive leadership, scientific and operational management, financial oversight, and AI platform development across the company’s activities.

What does Evaxion (EVAX) focus on with its AI-Immunology™ platform?

Evaxion focuses on using its proprietary AI-Immunology™ platform to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. The platform supports rapid, efficient target discovery, drug design and development, from early research through preclinical and clinical validation.

What types of vaccines are in Evaxion (EVAX)’s pipeline?

Evaxion’s pipeline includes both personalized and off-the-shelf cancer vaccine candidates, along with prophylactic vaccine candidates for infectious diseases. All candidates are described as addressing high unmet medical needs, reflecting the company’s goal of providing innovative, targeted treatment options for patients.

How large is Evaxion’s team supporting its AI-Immunology™ work?

Evaxion states that its team includes more than 40 experts covering the entire value chain from target discovery to clinical development. This multidisciplinary group underpins the company’s efforts to apply its AI-Immunology™ platform to vaccine design and progression into clinical stages.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 6.1 KB